Spravato
FDA Approves Spravato for Depression
In March 2019, the U.S. Food and Drug Administration (FDA) marked a significant milestone in the field of mental health by granting approval to esketamine nasal spray, marketed as Spravato®, for the treatment of treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) accompanied by suicidal thoughts or actions. Esketamine, the […]
Spravato: Depression & PTSD | Anew Era TMS & Psychiatry
Mental health issues, such as depression, can significantly impact a person, leading to reduced quality of life and daily functioning. Traditional oral antidepressants, while effective for many, may fall short for some, leaving them in search of alternative solutions. Enter Spravato (esketamine), a groundbreaking treatment that offers new hope for those grappling with depression. In this article, […]